Human African Trypanosomiasis : Progress and Stagnation - 04/02/19
, Jan Clerinx, MDRésumé |
Control efforts have considerably reduced the prevalence of human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in West/Central Africa and to Trypanosoma brucei rhodesiense in East Africa. Management of T brucei gambiense HAT has recently improved, with new antibody-based rapid diagnostic tests suited for mass screening and clinical care, and simpler treatments, including the nifurtimox-eflornithine combination therapy and the new oral drug fexinidazole to treat the second stage of the disease. In contrast, no major advance has been achieved for the treatment of T brucei rhodesiense HAT, a zoonosis that occasionally affects short-term travelers to endemic areas.
Le texte complet de cet article est disponible en PDF.Keywords : Human African trypanosomiasis, Trypanosoma brucei gambiense, Trypanosoma brucei rhodesiense, Clinical presentation, Diagnosis, Treatment
Plan
| None of the authors have conflict of interest to disclose for this article. |
Vol 33 - N° 1
P. 61-77 - mars 2019 Retour au numéro
Article précédent
- Malaria : What’s New in the Management of Malaria?
- Katherine Plewes, Stije J. Leopold, Hugh W.F. Kingston, Arjen M. Dondorp
- Visceral Leishmaniasis : Recent Advances in Diagnostics and Treatment Regimens
- Johan van Griensven, Ermias Diro
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?